Clinical Trials
23 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT01224288 2026-05-22
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT05225428 2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT05287945 2026-05-22
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Oncorena AB
Phase 1/2 Recruiting
NCT07227415 2026-05-22
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Phase 1/2 Recruiting
NCT00458536 2026-05-19
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
NCT07300241 2026-05-19
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
Phase 1 Recruiting
NCT05056077 2026-05-18
TTBF
University of California, San Francisco
Phase NA Active not recruiting
NCT05700461 2026-05-18
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Brigham and Women's Hospital
Phase 1 Recruiting
NCT07590310 2026-05-15
Clinical Application of CAIX-Targeted PET Imaging in Tumors
Peking University Cancer Hospital & Institute
Phase EARLY_PHASE1 Recruiting
NCT03470285 2026-05-14
IRMK01
University Hospital, Bordeaux
Phase NA Completed
NCT04195750 2026-05-14
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07011719 2026-05-14
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3 Recruiting
NCT06673329 2026-05-13
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Phase 1 Recruiting
NCT07244835 2026-05-13
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Phase 1 Recruiting
NCT06852638 2026-05-12
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
Phase 2 Recruiting
NCT06116253 2026-05-08
Advanced Diffusion Imaging in Renal Cancer Patients
NYU Langone Health
Phase NA Active not recruiting
NCT02535533 2026-05-06
SLM + Axitinib for Clear Cell RCC
University of Iowa
Phase 1/2 Completed
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT07555210 2026-05-06
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Vanderbilt-Ingram Cancer Center
Phase NA Recruiting
NCT07568444 2026-05-06
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
University of Southern California
Phase 2 Completed
NCT07195682 2026-05-05
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb
Phase 1 Recruiting
NCT03977571 2026-05-04
NORDIC-SUN
University of Aarhus
Phase NA Recruiting